Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...

Bristol-Myers Squibb gets rated a hold ... For example, from available Seeking Alpha valuation data its non-GAAP fwd P/E is a 64x multiple, around 200% above the sector average, while also ...

Hypocomplementaemia was associated with higher concentrations of all IgG subclasses and IgE (all p<0.05). After adjusting for serum ... Helmsley Charitable Trust, AstraZeneca, Bristol Myers Squibb, ...

under treatment (Wilcoxon test p = 0.735 and Z = −0.338 ... JS-A obtained honoraria for speaking engagements from Boehringer Ingelheim (Germany) and Bristol-Myers Squibb (Germany). LT: Saarland ...

Finally, a linear regression analysis demonstrated that theta-gamma coupling (β = 0.69, p < 0.001) was the most significant ... He has also received research support from Bristol-Myers Squibb ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q4 CY2024, with sales up 7.5% year on year to $12.34 ...

Shares in Bristol-Myers Squibb fell more than 4% in premarket trading Thursday, after the drug maker gave 2025 guidance that undershot analyst expectations. Bristol expects sales of about $45.5 ...